Population Pharmacokinetic-Pharmacodynamic Modelling of Angiotensin Receptor Blockade in Healthy Volunteers (Q57487974)

From Wikidata

Jump to navigation Jump to search

article

Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers

Language	Label	Description	Also known as
English	Population Pharmacokinetic-Pharmacodynamic Modelling of Angiotensin Receptor Blockade in Healthy Volunteers	article	Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers

Statements

scholarly article

0 references

Population Pharmacokinetic-Pharmacodynamic Modelling of Angiotensin Receptor Blockade in Healthy Volunteers (English)

0 references

Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers (English)

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

object named as

Thierry Buclin

2

0 references

author name string

Chantal Csajka

1

0 references

Karin Fattinger

3

0 references

Hans R. Brunner

4

0 references

J??r??me Biollaz

5

0 references

Thierry Buclin

2

0 references

Hans R Brunner

4

0 references

Jérôme Biollaz

5

0 references

language of work or name

0 references

publication date

2002

0 references

Clinical Pharmacokinetics

0 references

41

0 references

2

0 references

137-152

0 references

137-52

0 references

Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of Losartan on a Background of Hydrochlorothiazide in Patients With Hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiotensin II receptor antagonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuous, real-time, noninvasive monitor of blood pressure: Penaz methodology applied to the finger.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The importance of modeling interoccasion variability in population pharmacokinetic analyses

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Calculation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concepts and usefulness of pharmacokinetic-pharmacodynamic modelling.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Losartan with hydrochlorothiazide in the treatment of hypertension.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-response relationships following oral administration of DuP 753 to normal humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of noninvasive blood pressure recording by photoplethysmography in clinical studies using angiotensin challenges

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics with a Nonparametric Pharmacodynamic Model

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SC-52458, an Orally Active Angiotensin II-Receptor Antagonist: Inhibition of Blood Pressure Response to Angiotensin II Challenges and Pharmacokinetics in Normal Volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intestinal peptide transport systems and oral drug availability

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-invasive vs. invasive beat-to-beat monitoring of blood pressure

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Learning versus confirming in clinical drug development

1 reference

https://pubmed.ncbi.nlm.nih.gov/11888333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003088-200241020-00005

0 references

Dimensions Publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57487974&oldid=2222091433"